Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Amgen
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Thomas_J._Schall
|
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
oncology
autoimmune diseases inflammatory diseases orphan and rare diseases |
| gptkbp:foundedBy |
gptkb:Thomas_J._Schall
|
| gptkbp:foundedYear |
1997
|
| gptkbp:headquartersLocation |
gptkb:San_Carlos,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ChemoCentryx
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:avacopan
CCX140 CCX507 CCX872 |
| gptkbp:stockSymbol |
gptkb:CCXI
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.chemocentryx.com/
|
| gptkbp:bfsParent |
gptkb:AMGN
|
| gptkbp:bfsLayer |
7
|